These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 35228655)
1. The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy. Su PL; Chen JY; Chu CY; Chen YL; Chen WL; Lin KY; Ho CL; Tsai JS; Yang SC; Chen CW; Wu YL; Tseng YL; Chang CC; Yen YT; Lin CY; Lin CC; Su WC Sci Rep; 2022 Feb; 12(1):3319. PubMed ID: 35228655 [TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant immunotherapy plus chemotherapy achieved pathologic complete response in stage IIIB lung adenocarcinoma harbored EGFR G779F: a case report. Wang Y; Yang X; Tian X; Jia Z; Bing Z; Cao L; Gao C; Cao Z; Li S; Liang N Ann Palliat Med; 2020 Nov; 9(6):4339-4345. PubMed ID: 33183013 [TBL] [Abstract][Full Text] [Related]
3. Effects of EGFR driver mutations on pathologic regression in resectable locally advanced non-small cell lung cancer treated with neoadjuvant chemoradiation and completion surgery. Appel S; Bar J; Saad A; Marom EM; Urban D; Onn A; Gantz-Sorotsky H; Kremer RY; Ben-Nun A; Perelman M; Ofek E; Yacobi R; Daher S; Rasco A; Symon Z; Lawrence YR; Goldstein J Br J Radiol; 2023 Dec; 96(1152):20220763. PubMed ID: 37751214 [TBL] [Abstract][Full Text] [Related]
4. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009 [TBL] [Abstract][Full Text] [Related]
5. Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer. Zeng L; Zhou Y; Zhang X; Xu Q; Zhou C; Zeng F; Jiang W; Wang Z; Deng L; Yang H; Liu L; Xiong Y; Zhang B; Yang N; Zhang Y Lung Cancer; 2023 Apr; 178():134-142. PubMed ID: 36858002 [TBL] [Abstract][Full Text] [Related]
6. The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer. Shen Z; Teng M; Han L; Bian D; Zhang J; Zhu X; Qing Y; Hu S; Chen Y; Yao W; Yu H; Zhang L; Zhang P Cancer Immunol Immunother; 2023 Dec; 72(12):4235-4247. PubMed ID: 37932425 [TBL] [Abstract][Full Text] [Related]
7. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Corsini EM; Weissferdt A; Pataer A; Zhou N; Antonoff MB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Cascone T; Heymach JV; Swisher SG; Sepesi B Eur J Cardiothorac Surg; 2021 Jan; 59(1):100-108. PubMed ID: 32864702 [TBL] [Abstract][Full Text] [Related]
8. Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapy. Takahashi T; Sakai K; Kenmotsu H; Yoh K; Daga H; Ohira T; Ueno T; Aoki T; Hayashi H; Yamazaki K; Hosomi Y; Chen-Yoshikawa TF; Okumura N; Takiguchi Y; Sekine A; Haruki T; Yamamoto H; Sato Y; Akamatsu H; Seto T; Saeki S; Sugio K; Nishio M; Inokawa H; Yamamoto N; Nishio K; Tsuboi M Cancer Sci; 2022 Jan; 113(1):287-296. PubMed ID: 34689382 [TBL] [Abstract][Full Text] [Related]
10. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations. Kauffmann-Guerrero D; Tufman A; Kahnert K; Bollmann BA; Reu S; Syunyaeva Z; Schneider C; Manapov F; Huber RM; Golpon H Oncol Res Treat; 2020; 43(6):289-298. PubMed ID: 32268332 [TBL] [Abstract][Full Text] [Related]
11. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. Bai H; Wang Z; Chen K; Zhao J; Lee JJ; Wang S; Zhou Q; Zhuo M; Mao L; An T; Duan J; Yang L; Wu M; Liang Z; Wang Y; Kang X; Wang J J Clin Oncol; 2012 Sep; 30(25):3077-83. PubMed ID: 22826274 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. Saxena P; Singh PK; Malik PS; Singh N Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019 [TBL] [Abstract][Full Text] [Related]
13. Real-world outcomes of immunotherapy-based neoadjuvant therapy in resectable non-small cell lung cancer. Shen J; Gu L; Qi Y; Yao Y; Lu S; Chen Z Front Immunol; 2023; 14():1268251. PubMed ID: 37818382 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation. Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455 [TBL] [Abstract][Full Text] [Related]
15. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer]. Liu YT; Gao YS; Mao YS; Jiang J; Yang L; Yang JL; Hu XS; Zhou SY; Qin Y; Shi YK Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):480-485. PubMed ID: 32575944 [No Abstract] [Full Text] [Related]
16. An open, observational, three-arm clinical study of 2-3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis. Gu L; Wang X; Sun Y; Xu Y; Niu X; Zhao R; Yao Y; Jian H; Han Y; Wei J; Chen Z; Lu S Front Immunol; 2022; 13():938269. PubMed ID: 36059450 [TBL] [Abstract][Full Text] [Related]
17. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Pataer A; Shao R; Correa AM; Behrens C; Roth JA; Vaporciyan AA; Wistuba II; Swisher SG Cancer Med; 2018 Jun; 7(6):2405-2414. PubMed ID: 29673125 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation. Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599 [TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. Zhao ZR; Yang CP; Chen S; Yu H; Lin YB; Lin YB; Qi H; Jin JT; Lian SS; Wang YZ; You JQ; Zhai WY; Long H Oncoimmunology; 2021; 10(1):1996000. PubMed ID: 34712513 [TBL] [Abstract][Full Text] [Related]
20. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer. Liu X; Xing H; Liu H; Chen J Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]